

Clerk of the House of Representatives
 Legislative Resource Center
 B-106 Cannon Building
 Washington, DC 20515

Secretary of the Senate
 Office of Public Records
 332 Hart Building
 Washington, DC 20510

RECEIVED
 SECRETARY OF THE SENATE
 PUBLIC RECORDS

01 FEB 13 PM 2:01

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name American Association for Clinical Chemistry (AACC)			
2. Address <input type="checkbox"/> Check if different than previously reported 2101 L Street, NW, Suite 202, Washington, DC 20037			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____			
4. Contact Name Vince Stine	Telephone 202/835-8721	E-mail (optional) vstine@aacc.org	5. Senate ID # 1406-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report → Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> → \$ _____ <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> → \$ _____ <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
--	---

Signature V A Stine

Printed Name and Title Vincent G. Stine, Director, Government Affairs

LD-2 (REV. 6/98)

PAGE 1 of 4

Registrant Name AACC Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

(1) Joined with other laboratory organizations in writing Health Care Financing Administration (HCFA) about concerns involving draft Advanced Beneficiary Notice (ABN) for laboratory services.

(2) Joined with other laboratory groups in seeking the inclusion of provisions in proposed revisions to the Balanced Budget Act of 1997 (i.e., repeal of freeze on CPI update for laboratories and increase in phlebotomist drawing fee).

(3) Letter opposing the adoption of a 20 percent copayment for laboratory services under Medicare.

17. House(s) of Congress and Federal agencies contacted Check if None

(1) Health Care Financing Administration

(2) Senate Finance Committee

(3) Senate Finance Committee

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Vince Stine		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature V. G. Stine Date 2/12/01

Printed Name and Title Vincent G. Stine, Director, Government Affairs

Registrant Name AACC Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MM1 (cont.) (one per page)

16. Specific lobbying issues

(4) Wrote to key House Ways and Means Committee members supporting panel revisions to the BBA'97 legislation (i.e., eliminate consolidated billing requirement for Part B SNF services, authorize study of thyroid testing for screening purposes; reimbursing new technologies at 100 of the median and prohibiting lower payments for waiver tests.

17. House(s) of Congress and Federal agencies contacted Check if None

(4) House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Vince Stine		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature V. Stine Date 2/12/01

Printed Name and Title Vincent G. Stine, Director, Government Affairs

Registrant Name AACC Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- (1) Wrote to HHS with concerns about how FDA was waiving tests under the Clinical Laboratory Amendments of 1988 (CLIA'88)
- (2) Joint laboratory community letter to HHS expressing concerns with how FDA was waiving tests under CLIA'88.


17. House(s) of Congress and Federal agencies contacted Check if None

- (1) HHS
- (2) HHS

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Vince Stine		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/12/01

Printed Name and Title Vincent G. Stine, Director, Government Affairs